Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs.

Cancer immunology, immunotherapy : CII - 1 Aug 1994

Helfand S C, Soergel S A, MacWilliams P S, Hank J A, Sondel P M

Abstract excerpt

Four normal adult dogs received two consecutive weekly cycles of human recombinant interleukin-2 (IL-2) by continuous infusion for 4 days/week. The dose of IL-2 given to each dog was 3 x 10(6) units m-2 day-1. Toxicities consisted of mild vomiting, diarrhea, and lethargy to varying degrees in all the dogs. These side-effects were reversed when the treatment was discontinued. Fever, tachypnea, and weight gain were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Disease Models, Animal

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Interleukin-2

Share to Lymphocyte Activation

Share to Lymphocytes

Share to Phenotype

Share to Recombinant Proteins

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 8044833
DOI: 10.1007/BF01525313
PMCID: PMC11038981

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs.PMID 8044833Read ↗

Changes in lymphokine-activated killer activity in peripheral blood lymphocytes from canine transmissible venereal sarcoma models.Semantic proximity Read ↗

Phenotypic analysis and effects of sequential administration of activated canine lymphocytes on healthy beagles.Semantic proximity Read ↗

Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.Semantic proximity Read ↗

Analysis of liver lymphoid cell subsets pre- and post-in vivo administration of human recombinant interleukin 2 in a C57BL/6 murine system.Semantic proximity Read ↗

Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies.Semantic proximity Read ↗

Expansion of tumor-infiltrating lymphocytes from human tumors using the T-cell growth factors interleukin-2 and interleukin-4.Semantic proximity Read ↗

A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.Semantic proximity Read ↗

Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.Semantic proximity Read ↗

Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.Semantic proximity Read ↗

Generation and characterization of lymphokine-activated killer cells from non-Hodgkin's lymphoma patients.Semantic proximity Read ↗

Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.Semantic proximity Read ↗

Regulatory effects of interleukin-4 on tumor-infiltrating lymphocytes derived from human renal cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.